Modality
Small Molecule
MOA
VEGFi
Target
AuroraA
Pathway
Angiogenesis
MDSCSUCeliac
Development Pipeline
Preclinical
Sep 2019
→ Jul 2025
PreclinicalCurrent
NCT05175069
1,041 pts·Celiac
2019-09→2025-07·Active
1,041 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-089mo agoInterim· Celiac
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
Preclinical
Active
Catalysts
Interim
2025-07-08 · 9mo ago
Celiac
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05175069 | Preclinical | Celiac | Active | 1041 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |